Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19 WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that it has achieved full...

Innovation Pharmaceuticals and George Mason University Announce Public Release of Laboratory Testing Results Demonstrating Brilacidin’s COVID-19 Treatment Potential Preprint article details research conducted at George Mason’s Regional Biocontainment Laboratory: Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus causing...

Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic WAKEFIELD, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers...

Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method...

Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility; Demonstrates Potent and Rapid Virucidal Activity Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19 WAKEFIELD, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Innovation...